A. Lorenc and N. Robinson, A Review of the Use of Complementary and Alternative 470 Medicine and HIV: Issues for Patient Care, AIDS Patient Care STDs, vol.27, pp.503-513, 2013.

M. Musheke, V. Bond, S. Merten, M. D. Wong, D. E. Kanouse et al., Self-care practices and experiences of people living 472 with HIV not receiving antiretroviral therapy in an urban community of Lusaka, Zambia: 473 implications for HIV treatment programmes, AIDS Res. Ther, vol.10, p.12, 2013.

, Complementary and Alternative Medicine Use and Substitution for Conventional Therapy by 476 HIV-Infected Patients, J. Acquir. Immune Defic. Syndr, vol.33, pp.157-65, 2003.

J. O. Rivera, A. González-stuart, M. Ortiz, J. C. Rodríguez, J. P. Anaya et al., Herbal 478 product use in non-HIV and HIV-positive Hispanic patients, J. Natl. Med. Assoc, vol.479, pp.1686-91, 2005.

I. Bica, A. M. Tang, S. Skinner, D. Spiegelman, T. Knox et al., Use of 481 Complementary and Alternative Therapies by Patients With Human Immunodeficiency Virus 482

, Disease in the Era of Highly Active Antiretroviral Therapy, J. Altern. Complement. Med, vol.483, pp.65-76, 2003.

M. D. Furler, T. R. Einarson, S. Walmsley, M. Millson, and R. Bendayan, Use of 485 complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. 486 AIDS Patient Care STDs, vol.17, pp.155-68, 2003.

K. M. Fairfield, D. M. Eisenberg, R. B. Davis, H. Libman, and R. S. Phillips, Patterns of use, 488 expenditures, and perceived efficacy of complementary and alternative therapies in HIV-489 infected patients, Arch. Intern. Med, vol.158, pp.2257-64, 1998.

A. Sparber, J. C. Wootton, L. Bauer, G. Curt, D. Eisenberg et al., Use of 491 complementary medicine by adult patients participating in HIV/AIDS clinical trials, J. Altern. 492 Complement. Med. N. Y. N, vol.6, pp.415-437, 2000.

S. Dhalla, K. J. Chan, J. Montaner, and R. S. Hogg, Complementary and alternative 494 medicine use in British Columbia--a survey of HIV positive people on antiretroviral therapy, Complement. Ther. Clin. Pract, vol.12, p.10, 2006.

M. Bahall, Prevalence, patterns, and perceived value of complementary and alternative 497 medicine among HIV patients: a descriptive study, BMC Complement. Altern. Med, vol.498, p.11, 2017.

L. S. Lee, A. Andrade, and C. Flexner, Interactions between Natural Health Products and 500

, Antiretroviral Drugs: Pharmacokinetic and Pharmacodynamic Effects, Clin. Infect. Dis, vol.501, p.12, 2006.

S. N. Halpin, E. C. Carruth, R. P. Rai, E. J. Edleman, D. A. Fiellin et al.,

B. R. Bates, P. Kissinger, and R. E. Bessinger, 505 13. Marks C, Zúñiga ML. CAM Practices and Treatment Adherence Among Key 506 Subpopulations of HIV+ Latinos Receiving Care in the San Diego-Tijuana Border Region: A 507 Latent Class Analysis. Front, Complementary and Alternative Medicine among Persons living with HIV in the Era of 504 Combined Antiretroviral Treatment, vol.22, p.15, 1996.

V. Agnoletto, F. Chiaffarino, P. Nasta, R. Rossi, and F. Parazzini, Use of complementary and 511 alternative medicine in HIV-infected subjects, Complement. Ther. Med, vol.14, p.16, 2006.

I. Fogelman, L. Lim, R. Bassett, P. Volberding, M. A. Fischl et al., Prevalence 513 and patterns of use of concomitant medications among participants in three multicenter 514 human immunodeficiency virus type I clinical trials, AIDS Clinical Trials Group (ACTG). J, p.515

S. R. Smith, E. L. Boyd, and D. M. Kirking, Nonprescription and alternative medication use by, Acquir. Immune Defic. Syndr, vol.7, p.37, 1994.

P. R. Ravi, R. Vats, R. Thakur, S. Srivani, and A. N. , Effect of grapefruit juice and 568 ritonavir on pharmacokinetics of lopinavir in Wistar rats, Phytother. Res. PTR, vol.569, p.38, 1490.

D. Bailey, J. Spence, C. Munoz, and J. Arnold, Interaction of citrus juices with felodipine 571 and nifedipine, The Lancet, vol.337, p.39, 1991.

D. Marco, M. P. Edwards, D. J. Wainer, I. W. Ducharme, and M. P. , The effect of grapefruit juice 573 and seville orange juice on the pharmacokinetics of dextromethorphan: The role of gut 574 CYP3A and P-glycoprotein, Life Sci, vol.71, p.40, 1149.

S. R. Penzak, E. P. Acosta, M. Turner, D. J. Edwards, Y. Y. Hon et al., , p.576

, Seville Orange Juice and Grapefruit Juice on Indinavir Pharmacokinetics, J. Clin. Pharmacol, vol.577, p.41, 1165.

D. G. Bailey, Fruit juice inhibition of uptake transport: a new type of food-drug 579 interaction, Br. J. Clin. Pharmacol, vol.70, p.42, 2010.

G. K. Dresser, D. G. Bailey, B. F. Leake, U. I. Schwarz, P. A. Dawson et al., Fruit 581 juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the 582 oral availability of fexofenadine, Clin. Pharmacol. Ther, vol.71, p.43, 2002.

S. H. Yale and I. Glurich, Analysis of the inhibitory potential of Ginkgo biloba, Echinacea 584 purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 585 2C9, vitro Inhibition of CYP3A4 Metabolism, vol.11, p.587, 2005.

. Glycoprotein-mediated, Transport by Trade Herbal Products, Basic Clin. Pharmacol. Toxicol, vol.588, p.45, 2008.

M. Blonk, A. Colbers, A. Poirters, B. Schouwenberg, and D. Burger, Effect of Ginkgo Biloba 590 on the Pharmacokinetics of Raltegravir in Healthy Volunteers, Antimicrob. Agents 591 Chemother, vol.56, p.46, 2012.

S. M. Robertson, R. T. Davey, J. Voell, E. Formentini, R. M. Alfaro et al., , p.593

, Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy 594 subjects, Curr. Med. Res. Opin, vol.24, p.47, 2008.

D. Wiegman, K. Brinkman, and E. J. Franssen, Interaction of Ginkgo biloba with efavirenz, AIDS, vol.596, pp.1184-1185, 2009.

M. Naccarato, D. Yoong, K. Gough, J. C. Gorski, S. Huang et al., The 600 Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo, J. Int. Assoc. Physicians AIDS Care Chic. Ill, vol.11, pp.89-100, 2004.

, Echinacea Purpurea Significantly Induces Cytochrome P450 3A (CYP3A) but does not alter 604

. Lopinavir-ritonavir, Exposure in Healthy Subjects, Pharmacotherapy, vol.30, p.51, 2010.

J. Moltó, M. Valle, C. Miranda, S. Cedeño, E. Negredo et al., Herb-drug 606 interaction between Echinacea purpurea and darunavir-ritonavir in HIV

, Antimicrob. Agents Chemother, vol.55, p.52, 2011.

J. Moltó, M. Valle, C. Miranda, S. Cedeño, E. Negredo et al., Herb-Drug Interaction 609 between Echinacea purpurea and Etravirine in HIV-Infected Patients. Antimicrob. Agents 610 Chemother, vol.56, pp.5328-5359, 2012.

, Eur. Med, 2018.

C. Y. Malati, S. M. Robertson, J. D. Hunt, C. Chairez, R. M. Alfaro et al., 615 Influence of Panax ginseng on Cytochrome P450 (CYP)3A and P-glycoprotein, p.616

, Activity in Healthy Participants, J. Clin. Pharmacol, vol.52, p.55, 2012.

A. S. Etheridge, S. R. Black, P. R. Patel, J. So, and J. M. Mathews, , p.618

, Cytochrome P450 Inhibition and P-Glycoprotein Interaction with Goldenseal, Ginkgo biloba, p.619

, Grape Seed, Milk Thistle, and Ginseng Extracts and Their Constituents, Planta Med, vol.620, p.56, 2007.

G. D. Anderson, G. Rosito, M. A. Mohustsy, and G. W. Elmer, Drug Interaction Potential of Soy 622 Extract and Panax Ginseng, J. Clin. Pharmacol, vol.43, p.57, 2003.

B. J. Gurley, S. F. Gardner, M. A. Hubbard, D. K. Williams, W. B. Gentry et al.,

, Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans, Clin. 625 Pharmacol. Ther, vol.72, p.58, 2002.

A. S. Andrade, C. Hendrix, T. L. Parsons, B. Caballero, C. Yuan et al.,

, Pharmacokinetic and metabolic effects of American ginseng ( Panax quinquefolius ) in 628 healthy volunteers receiving the HIV protease inhibitor indinavir, BMC Complement. Altern, p.629

M. M. Med-;-calderón, C. L. Chairez, L. A. Gordon, R. M. Alfaro, J. A. Kovacs et al., 631 Influence of Panax ginseng on the Steady State Pharmacokinetic Profile of Lopinavir-632 Ritonavir in Healthy Volunteers, Pharmacother. J. Hum. Pharmacol. Drug Ther, vol.8, pp.1151-1159, 2008.

, Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: 636 a case report and brief review, Drug Metab. Pers. Ther, vol.27, p.61, 2012.

P. Chatterjee and M. R. Franklin, Human Cytochrome P450 Inhibition and Metabolic-638

J. W. Budzinski, B. C. Foster, S. Vandenhoek, and J. T. Arnason, An in vitro evaluation of 641 human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures, Drug Metab. Dispos, vol.31, p.63, 1391.

B. J. Gurley, S. F. Gardner, M. A. Hubbard, D. K. Williams, W. B. Gentry et al., In 644 vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 645 1A2, 2D6, 2E1, and 3A4/5 phenotypes, Clin. Pharmacol. Ther, vol.77, p.64, 2005.

R. S. Sandhu, R. P. Prescilla, T. M. Simonelli, and D. J. Edwards, Influence of Goldenseal Root 647 on the Pharmacokinetics of Indinavir, J. Clin. Pharmacol, vol.43, p.65, 2003.

B. J. Gurley, A. Swain, M. A. Hubbard, F. Hartsfield, J. Thaden et al.,

R. Savla, J. Browne, V. Plassat, K. M. Wasan, and E. K. Wasan, Review and analysis of FDA 653 approved drugs using lipid-based formulations, but not Kava Kava (Piper 650 methysticum), vol.651, pp.61-70, 2008.

D. Slain, J. R. Amsden, R. A. Khakoo, M. A. Fisher, D. Lalka et al., Effect of high-657 dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in 658 healthy volunteers, Pharmacotherapy, vol.655, p.69, 2005.

I. Song, J. Borland, S. Chen, P. Patel, T. Wajima et al., Effect of Food on 660 the Pharmacokinetics of the Integrase Inhibitor Dolutegravir, Antimicrob. Agents Chemother, vol.661, p.70, 2012.

I. Song, J. Borland, N. Arya, B. Wynne, and S. Piscitelli, Pharmacokinetics of dolutegravir 663 when administered with mineral supplements in healthy adult subjects, J. Clin. Pharmacol, vol.664, 2015.

, Eur. Med, vol.666, 2018.

, Eur. Med, vol.668, 2018.

, Eur. Med, vol.670, 2018.

J. L. Roberts, J. J. Kiser, J. T. Hindman, and A. L. Meditz, Virologic Failure with a Raltegravir-672

, Containing Antiretroviral Regimen and Concomitant Calcium Administration. Pharmacother. 673, J. Hum. Pharmacol. Drug Ther, vol.31, p.75, 2011.

D. M. Moss, M. Siccardi, M. Murphy, M. M. Piperakis, S. H. Khoo et al., Drug Approval Package: BIKTARVY(bictegravir, emtricitabine, and tenofovir 678 alafenamide) Tablets, Antimicrob. Agents Chemother, vol.676, p.77, 2012.

P. Patel, I. Song, J. Borland, A. Patel, Y. Lou et al., Pharmacokinetics of the HIV 681 integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and 682 multivitamins in healthy volunteers, J. Antimicrob. Chemother, 2011.

, Mineral-Content Water on the Tablet in Healthy Adults, vol.686, p.79, 2017.

S. L. Kang-birken, D. El-sayed, J. Prichard, . Hiv, and . Viral,

, Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and 689

C. Products, Report of 2 Cases, J. Int. Assoc. Provid. AIDS Care, vol.690, p.2019

C. W. James, S. Szabo, and N. D. Goldstein, The effect of multivitamins and 693 polyvalent cations on virologic suppression with integrase strand transfer inhibitors, AIDS, vol.34, p.81, 2020.

D. M. Brainard, E. J. Friedman, J. B. Breidinger, S. A. Tillan, M. D. Wenning et al., 696 Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics, J. Clin. 697 Pharmacol, vol.51, pp.422-429, 2011.

R. Krishna, M. L. Rizk, P. Larson, V. Schulz, F. Kesisoglou et al., , p.699

, Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir, Clin. Pharmacol. Drug 700 Dev, vol.7, p.83, 0196.

R. Dicenzo, V. Frerichs, P. Larppanichpoonphol, L. Predko, A. Chen et al., 702 Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy 703 adults, Pharmacotherapy, vol.26, p.84, 1255.

V. J. Navarro, H. Barnhart, H. L. Bonkovsky, T. Davern, R. J. Fontana et al., Liver 705 injury from herbals and dietary supplements in the

, Hepatol. Baltim. Md, vol.60, p.85, 2014.

M. C. Devries, A. Sithamparapillai, K. S. Brimble, L. Banfield, R. W. Morton et al.,

, Changes in Kidney Function Do Not Differ between Healthy Adults Consuming Higher-709 Compared with Lower-or Normal-Protein Diets: A Systematic Review and Meta-Analysis, J. 710 Nutr, vol.148, p.86, 1760.

W. M. Yoshizumi and C. Tsourounis, Effects of creatine supplementation on renal function

, J. Herb. Pharmacother, vol.4, pp.1-7, 2004.

V. Michaud, J. Turgeon, D. Flockhart, and M. A. Wainberg, Rôle de la pharmacogénétique 714 dans le métabolisme et le transport des antirétroviraux, Virologie, vol.15, p.88, 2011.

D. Marco, M. P. Edwards, D. J. Wainer, I. W. Ducharme, and M. P. , The effect of grapefruit juice 716 and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A 717 and P-glycoprotein, Life Sci, vol.71, p.89, 1149.

M. Chojkier, Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine 719 alkaloids, J. Hepatol, vol.39, p.90, 2003.

A. C. Muller, M. P. Ducharme, and I. Kanfer, Identification of Mechanism and Pathway of the 721 Interaction between the African Traditional Medicine, Sutherlandia Frutescens, p.722

, Antiretroviral Protease Inhibitor, Atazanavir, in Human Subjects Using Population 723

, Pharmacokinetic (PK) Analysis, J. Pharm. Pharm. Sci. Publ. Can. Soc. Pharm. Sci. Soc. Can

, Sci. Pharm, vol.21, p.91, 2018.

L. Galera, R. M. , R. Pascuet, E. , E. Mur et al., Juárez, vol.726

J. C. Giménez, M. A. Jalloh, P. J. Gregory, D. Hein, R. Cochrane et al., Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and 727 saquinavir, Eur. J. Clin. Pharmacol, vol.64, p.93, 2008.

N. R. Srinivas, Cranberry juice ingestion and clinical drug-drug interaction potentials; 732 review of case studies and perspectives, J. Pharm. Pharm. Sci. Publ. Can. Soc. Pharm. Sci, p.733

;. Société-can, J. C. Gorski, S. Huang, A. Pinto, M. A. Hamman et al., The 735 Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo, Clin. 736 Pharmacol. Ther, vol.16, pp.289-303, 2004.

, Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter 739 lopinavir-ritonavir exposure in healthy subjects, Pharmacotherapy, vol.30, p.96, 2010.

J. Moltó, M. Valle, C. Miranda, S. Cedeño, E. Negredo et al., Herb-drug interaction 741 between Echinacea purpurea and etravirine in HIV-infected patients, Antimicrob. Agents 742 Chemother, vol.56, pp.5328-5359, 2012.

, Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications, AIDS, vol.745, pp.1243-1244, 2008.

B. H. Hellum and O. G. Nilsen, In vitro inhibition of CYP3A4 metabolism and P-747 glycoprotein-mediated transport by trade herbal products, Basic Clin. Pharmacol. Toxicol, vol.748, p.99, 2008.

D. Wiegman, K. Brinkman, E. Franssen, M. Naccarato, D. Yoong et al., 754 Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity 755 in healthy participants, J. Int. Assoc. Physicians AIDS Care Chic. Ill, vol.52, pp.932-941, 2009.

A. S. Etheridge, S. R. Black, P. R. Patel, J. So, and J. M. Mathews, An in vitro evaluation of 757 cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, 758 grape seed, milk thistle, and ginseng extracts and their constituents, Planta Med, vol.759, pp.731-772, 2007.

A. Andrade, C. Hendrix, T. L. Parsons, B. Caballero, C. Yuan et al.,

M. M. Calderón, C. L. Chairez, L. A. Gordon, R. M. Alfaro, J. A. Kovacs et al., Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy 762 volunteers receiving the HIV protease inhibitor indinavir, BMC Complement. Altern. Med, vol.763, pp.50-764, 2008.

, Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir 766 in healthy volunteers, Pharmacotherapy, vol.34, pp.1151-1159, 2014.

, chinense): Phytochemistry, pharmacology 768 and safety in the perspective of traditional uses and recent popularity, Planta Med, vol.769, pp.7-19, 2010.

P. Chatterjee and M. R. Franklin, Human cytochrome p450 inhibition and metabolic-771 intermediate complex formation by goldenseal extract and its methylenedioxyphenyl 772 components, Drug Metab. Dispos. Biol. Fate Chem, vol.31, pp.1391-1398, 2003.

J. W. Budzinski, B. C. Foster, S. Vandenhoek, and J. T. Arnason, An in vitro evaluation of 774 human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures

, Phytomedicine Int. J. Phytother. Phytopharm, vol.7, pp.273-82, 2000.

B. J. Gurley, A. Swain, M. A. Hubbard, F. Hartsfield, J. Thaden et al.,

, Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper 778 methysticum), inhibits human CYP3A activity in vivo, Clin. Pharmacol. Ther, vol.83, pp.61-70, 2008.

R. S. Sandhu, R. P. Prescilla, T. M. Simonelli, and D. J. Edwards, Influence of goldenseal root on 780 the pharmacokinetics of indinavir, J. Clin. Pharmacol, vol.43, pp.1283-1291, 2003.

P. S. Fasinu, B. J. Gurley, and L. A. Walker, Clinically Relevant Pharmacokinetic Herb-drug 782 Interactions in Antiretroviral Therapy, Curr. Drug Metab, vol.17, pp.52-64, 2015.

S. Engdal and O. G. Nilsen, In vitro inhibition of CYP3A4 by herbal remedies frequently 784 used by cancer patients, Phytother. Res. PTR, vol.23, pp.906-918, 2009.

S. Misaka, K. Kawabe, S. Onoue, J. P. Werba, M. Giroli et al., Effects of green 786 tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and 787 intestinal microsomes, Drug Metab. Pharmacokinet, vol.28, pp.244-253, 2013.

M. Unger and A. Frank, Simultaneous determination of the inhibitory potency of herbal 789 extracts on the activity of six major cytochrome P450 enzymes using liquid 790 chromatography/mass spectrometry and automated online extraction, Rapid Commun. Mass 791 Spectrom. RCM, vol.18, pp.2273-81, 2004.

N. Romiti, G. Tramonti, A. Corti, and E. Chieli, Effects of Devil's Claw (Harpagophytum 793 procumbens) on the multidrug transporter ABCB1/P-glycoprotein, Phytomedicine Int. J. 794 Phytother. Phytopharm, vol.16, pp.1095-100, 2009.

E. Cordova, L. Morganti, and C. Rodriguez, Possible Drug-Herb Interaction between Herbal 796

T. G. Monera-penduka, C. C. Maponga, A. R. Wolfe, L. Wiesner, G. D. Morse et al., 799 Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-800 infected adults: a one sequence cross-over study, Supplement Containing Horsetail (Equisetum arvense) and Antiretroviral Drugs, vol.16, pp.1-7, 2017.

J. Doehmer, G. Weiss, G. P. Mcgregor, and K. Appel, Assessment of a dry extract from milk 802 thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities

. Toxicol and . Vitro, Int. J. Publ. Assoc. BIBRA, pp.25-46, 2011.

S. Savranoglu and T. B. Tumer, Inhibitory effects of spirulina platensis on carcinogen-805 activating cytochrome P450 isozymes and potential for drug interactions, Int. J. Toxicol, vol.806, pp.376-84, 2013.

A. Al-thukair, A. A. Alam, M. A. Abbas, F. A. Al-mohizea, A. M. et al., Appiah-Opong R, Commandeur JNM, van Vugt-Lussenburg B, Vermeulen NPE. 812 Inhibition of human recombinant cytochrome P450s by curcumin and curcumin 813 decomposition products, Eur. J. Drug 810 Metab. Pharmacokinet, vol.40, pp.83-91, 2007.

T. Lefebvre, B. C. Foster, C. E. Drouin, A. Krantis, J. F. Livesey et al., In vitro activity 815 of commercial valerian root extracts against human cytochrome P450 3A4, J. Pharm. Pharm

. Sci, Can. Soc. Pharm. Sci. Société Can. Sci. Pharm, vol.7, pp.265-73, 2004.

, Eur. Med, vol.818, 2018.

T. Abacavir,